SUMMARY
Cardiotoxicity, defined as toxicity that affects the heart, is one of the most common adverse drug effects. Numerous drugs have been shown to have the potential to induce lethal arrhythmias by affecting cardiac electrophysiology, which is the focus of current preclinical testing. However, a substantial number of drugs can also affect cardiac function beyond electrophysiology. Within this broader sense of cardiotoxicity, this review discusses the key drug-protein interactions known to be involved in cardiotoxic drug response. We cover adverse effects of anticancer, central nervous system, genitourinary system, gastrointestinal, antihistaminic, anti-inflammatory, and anti-infective agents, illustrating that many share mechanisms of cardiotoxicity, including contractility, mitochondrial function, and cellular signaling.

INTRODUCTION
Concerns regarding cardiac safety are among the top reasons for drug withdrawal from clinical trials and the market. Strict examination of cardiac safety liabilities has resulted in a sustained increase in attrition rates at all phases of drug development over the last decades. This increased attrition rate is illustrated in Figure 1, summarizing by therapeutic area all drugs withdrawn from the market due to cardiac safety concerns, as well as their commercialization lifespans. The latter have been greatly reduced over the last decades. Although this process of continuous pharmacovigilance greatly reassures the safety of new commercialized compounds, it also highlights that many constituent molecular processes underlying cardiotoxicity have yet to be comprehensively understood. This is substantially challenging for several scientific reasons. First, the spectrum of cardiotoxicity is broad, spanning from arrhythmia, to myocardial dysfunction, to terminal heart failure. In addition, the extent of the effects depends on exposure and varies among patients. Finally, adverse drug effects have been shown to depend on the gender, age, and genetic background of the individual.

Drug-induced cardiotoxicity thus imposes substantial limits on drug development, as well as in the clinical management of existing drugs. Particularly critical across safety liabilities is the risk to induce potentially lethal arrhythmias via direct interactions with cardiac electrophysiology. However, recent studies have shown that a considerable number of drugs in use can also disrupt cardiac function by impairing myocardial metabolism and cardiac structure. These include anticancer therapies associated with myocardial apoptosis, neurodegenerative disease agents with severe risk of fibrotic valvular heart disease, or anti-bacterial and antiviral treatments leading to mitochondrial damage.

Multiple drug classes have the potential to induce cardiovascular adverse effects in patients. In this review, we summarize the drug-protein mechanisms by which drug-induced cardiotoxicity may develop. We provide a detailed review of 78 drugs with known cardiac adverse effects, 27 of which have been withdrawn from the market due to cardiotoxicity (Figure 1; Table 1). We cover adverse effects and cardiotoxic mechanisms of anticancer, central nervous system (CNS), genitourinary system, gastrointestinal, antihistaminic, anti-inflammatory, and anti-infective agents. We illustrate that they have common modes of action on cardiac function and on adverse cardiac events. Even though many of these points could be discussed in detail, we expect these findings will provide reliable guidance in identifying new critical pharmacophores, as well as key assays for the evaluation of drug-induced cardiotoxicity.

Main molecular mechanisms of drug cardiotoxicity
Cardiotoxicity generally results from the simultaneous interruption of key myocardial functions and viabilities. In this section, we focus on adverse drug effects via the disruption of electrophysiology, contractility, mitochondrial toxicity, growth factor, and cytokine regulation. These mechanisms of drug cardiotoxicity are summarized in Figure 2, together with the main types of therapeutic agents manifesting such risks. Importantly, the mechanisms underlying adverse cardiac events are often multifactorial, exerting their action through complex cell signaling pathways. The main signaling pathways underlying drug cardiotoxicity, further developed in the
subsequent sections of this review paper, are illustrated in Figure 3.

**Electrophysiology**

**Direct block**

hERG-encoded channels, carrying the rapid delayed rectifier current (IKr), are main determinants of cardiac repolarization and proarrhythmic events (Figure 3, top left). Therefore, in the last decades, preclinical testing for cardiac adverse events has primarily focused on screening assays of hERG channel inhibition.\(^97\) However, the biological role of hERG channels is not limited to their electrophysiological function. hERG-encoded channels are also involved in cell proliferation and malignant cell apoptosis,\(^98\) and reducing hERG expression in gliomas has been proposed as a target for antineoplastic therapy.\(^99\) Beyond IKr block, drugs often interact with multiple channels. Recent work on multichannel action and its connection to adverse effects has resulted in significantly improved toxicity prediction.\(^100,101\) Evidence also suggests that the electrophysiological implications of drug-induced block of hERG channels could be alleviated by interactions with other channels.\(^102\) Adverse electrophysiological effects can be accentuated by several factors, especially heart disease. For example, diabetes has been shown to abate the amplitude of multiple ionic currents,\(^103\) enhancing susceptibility to adverse effects.

** Trafficking inhibition**

In addition to direct hERG channel block, multiple pharmacological agents can cause hERG deficiency (with hERG channel block or independently) by the inhibition of its biogenesis and trafficking. A detailed schematic of the subcellular processes involved in hERG biogenesis, trafficking, and degradation, together with established pathways of drug-induced IKr deficiency, is presented in Figure 4. Drugs with reported effects on hERG trafficking impairment are listed in Table 1. Compared with the fast action of acute inhibition, hERG trafficking impairment manifests with timescales of hours to days.

For example, arsenic trioxide (Figure 4), extensively used in cancer treatment, interacts with chaperones Hsp70 and Hsp90, altering the folding process of hERG. As a result, it has been shown to affect hERG maturation in HEK293 cell lines.\(^104\) Folding inhibition also has been proposed as a mechanism of the dual tumor suppression and carcinogenicity of arsenic trioxide.\(^105\) Similarly, the antidiarrheal berberine and its derivative, dihydroberberine (Figure 4), have been shown to impair hERG folding in both HEK293 cell lines and guinea pig ventricular cardiomyocytes.\(^106,107\) The inhibition of folding by those drugs results in the reduction of the mature glycosylated form of 155 kDa hERG, which can be easily measured along with immature hERG (135 kDa). Accumulation of unfolded proteins activates the unfolded protein response pathway, as shown in HEK293 cells incubated with berberine\(^107\) and in mouse vascular endothelial cell lines incubated with arsenic trioxide.\(^108\) For the anti-infective drug pentamidine (Figure 4), mature hERG deficiency was identified as the result of reduced immature transport in HEK293 cell lines and neonatal rat cardiomyocytes.\(^81\)
| Drug               | Introduced–withdrawn | Mechanism of action with targets | Side effects on cardiac function | Mechanism of cardiac toxicity                                                                 | References |
|--------------------|----------------------|----------------------------------|----------------------------------|------------------------------------------------------------------------------------------------|------------|
| **Antineoplastic agents** |                      |                                   |                                  |                                                                                                |            |
| 5-fluorouracil     | 2000–NA              | DNA cross-linking                 | arrhythmias, myocardial ischemia, heart failure | TXA₂ activation leading to cardiac remodeling, electrolyte imbalances | 9,10       |
| Arsenic trioxide   | 2000–NA              | inhibition of TXNRD1; activation of IKBKB, JUN, MAPK3, MAPK1 | QT prolongation, tachycardia      | hERG trafficking inhibition                                                                 | 11,12      |
| Bevacizumab        | 2016–NA              | blocker of VEGFA                  | heart failure                    | disruption of cardiomyocyte survival via VEGF signaling inhibition | 13         |
| Bortezomib         | 2003–NA              | inhibition of PSMB5, PSMB1        | heart failure, arrhythmia         | hERG trafficking inhibition                                                                 | 14,15      |
| Cisplatin          | 1978–NA              | DNA cross-linking                 | arrhythmias, myocardial ischemia, heart failure | TXA₂ activation leading to cardiac remodeling, electrolyte imbalance | 9,16       |
| Cytarabine         | 1966–NA              | DNA intercalation, inhibition of DNA polymerase β | bradycardia, heart failure, ischemia | unknown                                                                                           | 17,18      |
| Daunorubicin       | 1980–NA              | inhibition of TOP2B               | arrhythmias, heart failure        | mitochondrial toxicity, oxidative stress leading to apoptosis | 19,20      |
| Dasatinib          | 2016–NA              | Bcr-Abl kinase, EPHA2, LCK, YES1  | heart failure                    | disruption of cardiomyocyte survival via VEGF signaling inhibition | 21         |
| Docetaxel          | 1991–NA              | inhibition of β subunit of tubulin, Bcl-2 | bradycardia, myocardial ischemia, heart failure | apoptosis of cardiac endothelial cells                                                                 | 22,23      |
| Doxorubicin        | 1978–NA              | DNA intercalation, inhibition of TOP2B | arrhythmias, heart failure         | mitochondrial toxicity, oxidative stress leading to apoptosis | 19,24      |
| Idarubicin         | 1989–NA              | inhibition of TOB2B               | arrhythmias, heart failure        | mitochondrial toxicity, oxidative stress leading to apoptosis | 19         |
| Imatinib           | 2016–NA              | Bcr-Abl kinase, KIT, RET          | systolic heart failure, heart failure, left ventricular dysfunction | release of Bcl-2 proteins leading to mitochondrial toxicity, oxidative stress leading to apoptosis, disruption of cardiomyocyte survival via VEGF signaling inhibition | 21         |
| Ipilimumab         | 2011–NA              | inhibition of CTLA-4              | lethal myocarditis                | unknown                                                                                           | 25,26      |
| Lapatinib          | 2004–NA              | blocking of EGFR, HER2            | left ventricular ejection fraction, congestive heart failure | disruption of cardiomyocyte survival via EGF signaling inhibition | 27         |
| Nilotinib          | 2005–NA              | inhibition of ABL1, blocking of KIT | myocardial ischemia               | disruption of cardiomyocyte survival via VEGF signaling inhibition | 21         |
| Nivolumab          | 2017–NA              | inhibition of PD-1                | lethal myocarditis                | unknown                                                                                           | 25,26      |
| Paclitaxel         | 1995–NA              | inhibition of β subunit of tubulin, Bcl-2 | bradycardia, myocardial ischemia, heart failure | apoptosis of cardiac endothelial cells                                                                 | 28,29      |
| Romidepsin         | 2009–NA              | inhibition of HDAC1, HDAC2, HDAC4, HDAC6, ABCC1 | QT prolongation, myocardial infarction | hERG trafficking inhibition                                                                 | 30         |

(Continued on next page)
Table 1.  Continued

| Drug                | Introduced–withdrawn | Mechanism of action with targets                           | Side effects on cardiac function                        | Mechanism of cardiac toxicity | References |
|---------------------|----------------------|------------------------------------------------------------|----------------------------------------------------------|-------------------------------|------------|
| Sorafenib           | 2006–NA              | inhibition of BRAF kinase, FLT1, FLT3, FGFR1, KIT, PDGFRB, RAF1, RET, VEGFR2, VEGFR3 | heart failure, myocardial ischemia, QT prolongation      | disruption of cardiomyocyte survival via VEGF signaling inhibition | 31         |
| Sunitinib           | 2006–NA              | inhibition of PDGFRB, FLT1, FLT3, FLT4, KDR, KIT, CSF1R, PDGFRα | long QT, left ejection fraction, myocardial infarction    | disruption of cardiomyocyte survival via VEGF signaling inhibition | 32         |
| Trastuzumab         | 2016–NA              | blocker of HER2                                             | heart failure, tachycardia                               | disruption of cardiomyocyte survival via EGF signaling inhibition | 33,34      |
| Vandetanib          | 2011–NA              | inhibition of VEGFA, EGFR, PTK6, TEK                        | long QT                                                  | disruption of cardiomyocyte survival via VEGF and EGF signaling inhibition | 27,35      |
| Vinblastine         | 1960s–NA             | inhibition of α, β, and δ subunits of tubulin               | myocardial ischemia, heart failure                       | apoptosis of cardiac endothelial cells                       | 36         |
| Anti-inflammatory agents |                     |                                                            |                                                          |                                                               |            |
| Diclofenac          | 1986–NA              | inhibition of COX-1, COX-2, SCN4A, ASIC1; potentiation of ALOX5 | myocardial infarction                                   | blocking prostacyclin synthase                                | 37,38      |
| Etoricoxib          | 2002–2007            | inhibition of COX-2                                         | thrombotic events                                        | blocking prostacyclin synthase                                | 37,38      |
| Ibuprofen           | 1978–NA              | inhibition of COX-1, COX-2                                  | myocardial infarction, hypertension                      | blocking prostacyclin synthase                                | 37,38      |
| Indomethacin        | 1966–NA              | inhibition of COX-1, COX-2, PLA2G2A, GLO1; activation of PPARG | myocardial infarction                                   | blocking prostacyclin synthase                                | 37,38      |
| Naproxen            | 1978–NA              | inhibition of COX-1, COX-2                                  | myocardial infarction                                    | blocking prostacyclin synthase                                | 37         |
| Rofecoxib           | 1999–2004            | inhibition of COX-2                                         | myocardial infarction                                    | blocking prostacyclin synthase                                | 39         |
| Central nervous system agents |             |                                                            |                                                          |                                                               |            |
| Benfluorex          | 1972–2009            | blocking of 5-HT1B                                          | valvular heart disease                                   | HTR2B-induced activation of TGF-β signaling                  | 40         |
| Bupivacaine         | 1965–NA              | inhibition of SCN10A                                        | ventricular arrhythmias, myocardial depression           | inhibition of voltage-gated sodium channel, mitochondrial toxicity | 41         |
| Chlorphentermine    | 1966–1969            | blocking of 5-HTs                                          | pulmonary heart disease                                  | HTR2B-induced activation of TGF-β signaling                  | 42         |
| Clozapine           | 1991–NA              | blocking of DRD2, HTR2A, DRD1, DRD3, DRD4, HTR1A, HTR1B, HTR1D, HTR1E, HTR2C, HTR3A, HTR6, HTR7, HRR1, HRR4, ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 | myocarditis, cardiomyopathy                               | unknown                                              | 43,44      |

(Continued on next page)
| Drug                  | Introduced–withdrawn | Mechanism of action with targets | Side effects on cardiac function                                                                 | Mechanism of cardiac toxicity                                                                 | References |
|----------------------|----------------------|-----------------------------------|---------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|------------|
| Cocaine              | 1884–NA              | inhibition of SLC6A3, SLC6A2, SLC6A4, SCN5A | left ventricular hypertrophy, arrhythmias                                                        | inhibition of voltage-gated sodium channel, mitochondrial toxicity                                | 45         |
| Dexfenfluramine       | 1996–1997            | inhibition of SLC6A4              | valvular heart disease                                                                            | HTR2B-induced activation of TGF-β signaling                                                    | 46,47      |
| Ergotamine            | 1925–NA              | activation of ADRA1A, DRD2, HTR1B, HTR1D, HTR2A | valvular heart disease                                                                            | induction of fibrosis via HTR2B-induced activation of TGF-β signaling                           | 48         |
| Fenfluramine          | 1973–1997            | inhibition of SLC6A4, blocking of HTR2B | valvular heart disease                                                                            | HTR2B-induced activation of TGF-β signaling                                                    | 47,49      |
| Fluoxetine            | 1990–NA              | inhibition of SLC6A4              | bradycardia                                                                                       | inhibition of I_{CaL}, I_{Kr}, hERG trafficking inhibition                                      | 50         |
| Haloperidol           | 1967–NA              | blocking of DRD1, DRD2, GRIN2B; inverse activation of DRD3 | QT prolongation, TdP, sudden cardiac death                                                        | inhibition of I_{Kr}, I_{NaL}, I_{CaL}                                                       | 51         |
| Levomethadyl acetate  | 1991–2003            | activation of OPRM1               | QT prolongation, TdP                                                                             | inhibition of I_{Kr}                                                                              | 52         |
| Lidoceaine            | 1944–NA              | inhibition of SCN10A, SCN9A, SCN5A; blocking of EGRFR | bradycardia, cardiac arrest                                                                      | inhibition of voltage-gated sodium channel, mitochondrial toxicity                              | 53,54      |
| Methysergide          | 1965–NA              | blocking of HTR2A, HTR2B, HTR2C, HTR7; activation of HTR1A; binding HTR1B, HTR1E, HTR1F | valvular heart disease                                                                            | induction of fibrosis via HTR2B-induced activation of TGF-β signaling                           | 6          |
| Pergolide             | 1987–NA              | blocking of ADRA1B, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1D, HTR2B, HTR2C | valvular heart disease                                                                            | induction of fibrosis via HTR2B-induced activation of TGF-β signaling                           | 6,55       |
| Phentermine           | 1959–1997            | inhibition of SLC6A2, SLC6A3, SLC6A4; blocking of MAOA, MAOB | QT prolongation, TdP                                                                             | inhibition of I_{Kr}                                                                              | 47         |
| Propoxyphene          | 1957–2010            | activation of OP1, OP2, OP3        | QT prolongation, TdP                                                                             | inhibition of I_{Kr}                                                                              | 56         |
| Sertindole            | 1998–2014            | blocking of DRD2, HTR2A, HTR2C, HTR6 | QT prolongation, TdP                                                                             | inhibition of I_{Kr}                                                                              | 57         |
| Sibutramine           | 2001–2002            | inhibition of SLC6A4, SLC6A2, SLC6A3 | myocardial infarction                                                                            | inhibition of I_{Kr}                                                                              | 58,59,60   |
| Thioridazine          | 1978–NA              | blocking of ADRA1A, ADRA1B, DRD1, DRD2, HTR2A; inhibition of KCNH2 | QT prolongation, TdP, sudden cardiac death                                                        | inhibition of I_{NaL}, I_{Kr}                                                               | 51         |
| Venlafaxine           | 1986–NA              | inhibition of SLC6A4, SLC6A2      | QT prolongation, arrhythmias                                                                      | inhibition of I_{Na}                                                                               | 61,62      |
| Ziprasidone           | 2001–NA              | inhibition of ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HTR2A, HTR1B, HTR1D, HTR1E, HTR2C, HTR3A, HTR6, HTR7, HRH1; activation of HTR1A | QT prolongation, TdP, sudden cardiac death                                                        | inhibition of I_{Kr}                                                                              | 51         |

(Continued on next page)
| Drug                  | Introduced–withdrawn | Mechanism of action with targets                                                                 | Side effects on cardiac function                                      | Mechanism of cardiac toxicity                        | References |
|----------------------|----------------------|--------------------------------------------------------------------------------------------------|------------------------------------------------------------------------|-------------------------------------------------------|------------|
| Cisapride            | 1980–2000            | blocking of HTR2A, HTR3A, HTR4; inhibition of KCNH2                                             | ventricular arrhythmia, QT prolongation, TdP, cardiac arrest            | inhibition of I_{Kr}                                  | 63         |
| Loperamide           | 1976–NA              | blocking of OPRM1, OPRD1, OPRK; inhibition of POMC; modulation of CALM1                           | cardiac arrest, QT prolongation, ventricular tachycardia, TdP           | inhibition of voltage-gated calcium channels           | 64,65      |
| Omeprazole           | 1987–NA              | inhibition of ATP4A                                                                                 | acute myocardial infarction, heart failure                              | disruption of NO synthesis via ADMA production       | 66         |
| Tegaserod            | 1997–2007<sup>b</sup> | blocking of HTR2A, HTR2B, HTR2C, HTR4                                                             | ischemia                                                               | inhibition of I_{Kr}                                  | 67         |
| Terodiline           | 1975–1991            | blocking of muscarinic acetylcholine receptors                                                    | ventricular tachycardia, cardiac death                                 | inhibition of I_{Kr}, blocking of calcium cycling     | 68,69      |
| Astemizole           | 1992–1999            | blocking of HRH1, inhibition of KCNH2                                                              | long QT syndrome, TdP                                                  | inhibition of I_{Kr}                                  | 70,71      |
| Diphenhydramine      | 1946–NA              | blocking of HRH1, CHRM2                                                                             | QT prolongation                                                       | inhibition of I_{Kr}                                  | 72,73      |
| Terfenadine          | 1985–1997            | blocking of HRH1                                                                                   | QT prolongation, TdP                                                  | inhibition of I_{Kr}                                  | 74         |
| Azidothymidine       | 1989–NA              | inhibition of Pol, TERT                                                                             | dilated cardiomyopathy                                               | mitochondrial toxicity                                | 75         |
| Azithromycin         | 1988–NA              | inhibition of 23S rRNA, rplD, rplV, PADI4                                                           | QT prolongation, TdP, cardiac death                                   | mitochondrial toxicity                                | 76         |
| Clarithromycin       | 1993–NA              | inhibition of rplU, SLC01B1, SLC01B3                                                                | QT prolongation, myocardial infarction, arrhythmias, cardiac death     | mitochondrial toxicity                                | 77,78      |
| Erythromycin         | 1955–NA              | inhibition of 23S rRNA, MLNR, KCNH2, ALB                                                           | QT prolongation, ventricular tachycardia, TdP, ventricular fibrillation | mitochondrial toxicity                                | 7          |
| Grepafloxacin        | 1998–1999            | inhibition of gyrA, parC                                                                           | QT prolongation                                                       | inhibition of I_{Kr}                                  | 79         |
| Sofosbuvir           | 2013–NA              | inhibition of NS5b                                                                                  | bradycardia                                                           | unknown                                               | 80         |
| Sparfloxacin         | 1997–2001            | inhibition of parC, gyrA, TOP2A                                                                     | QT prolongation                                                       | inhibition of I_{Kr}                                  | 79         |
| Pentamidine          | 1975–NA              | inhibition of RNA transfer                                                                         | QT prolongation, arrhythmias                                           | hERG trafficking inhibition                          | 81,82–84   |

**Cardiovascular agents**

| Drug                  | Introduced–withdrawn | Mechanism of action with targets                                                                 | Side effects on cardiac function                                      | Mechanism of cardiac toxicity                        | References |
|----------------------|----------------------|--------------------------------------------------------------------------------------------------|------------------------------------------------------------------------|-------------------------------------------------------|------------|
| Buflomedil           | 1970s–2011           | blocking of ADRA1A, ADRA2A                                                                         | QT prolongation, cardiac arrest                                       | unknown                                              | 85,86      |
| Dofetilide           | 2000–2004            | inhibition of KCNH2, KCNK2, KCNJ12                                                               | QT prolongation, TdP                                                  | inhibition of I_{Kr}                                  | 87         |
| Encainide            | 1987–1991            | inhibition of SCN5A                                                                                | QT prolongation                                                       | inhibition of I_{Kr}                                  | 88         |
| Lidoflazine          | 1973–1989            | blocking of calcium channels                                                                       | QT prolongation                                                       | inhibition of I_{Kr}                                  | 89         |
| Mibefradil           | 1997–1998            | inhibition of CACNA1G, CACNA1H, CACNA1C, CACNA1D, CACNA1F, CACNA1I, CACNA1S, CACNB1, CACNB2, CACNB3, CACNB4 | QT prolongation                                                       | inhibition of Kir                                     | 90,91      |

(Continued on next page)
Cardiac glycosides (Figure 4), specifically Na+/K+-ATPase inhibitors with known QT prolongation risk, reduce hERG trafficking in HEK293 lines and in guinea pig ventricular cardiomyocytes. Incubation with digoxin, digoxin, and ouabain resulted in a significant reduction of mature hERG. Later evidence showed that digoxin-induced hERG trafficking inhibition is a result of the low intracellular potassium concentration caused by Na+/K+-ATPase inhibition. Moreover, digoxin has been reported to generally enhance protein degradation through a lysosomal pathway.

The lipid-lowering compound probucol also causes QT prolongation without a direct block of hERG channels (Figure 4). This is believed to result from trafficking disruption, as shown in neonatal rat ventricular cardiomyocytes and later in HEK293 cells, in which enhanced degradation of mature hERG via neddylation was indicated as a mechanism. As with probucol, desipramine accelerates degradation of mature hERG in HEK293 cells without interfering with Hsp90 and Hsp70 chaperones. A study of c少吃 in HEK293 cells expressing hERG, KCNJ2, and KCNB1 genes showed it inhibits both the function and the trafficking of Kir3.1, encoded by KCNJ2, and hERG channels, but not Kv2.1, encoded by KCNB1, and hERG channels, but not Kv2.1, encoded by KCNB1. hERG trafficking effects were 5- to 10-fold more potent than the acute block of the channel.

**Contractility**

Drugs have also been observed to affect contractility, the most fundamental heart function. Cardiomyocytes connect electro-mechanically with one another and the extracellular matrix via gap junctions, key molecular regulators for intercellular communication and coordinated contraction. In addition, calcium cycling, a complex process involving multiple regulatory molecules, is essential for contraction.

Specifically, the calcium/calmodulin-dependent protein kinase II (CaMKII) regulates calcium cycling via phosphorylation of its targets on both the cellular membrane and the sarcoplasmic reticulum (Figure 3, center). Accordingly, CaMKII inhibition has been shown to have potential efficacy for antiarrhythmic therapy. Nitric oxide (NO) further regulates intracellular calcium, promotes vascular relaxation, and inhibits platelet aggregation. In cardiomyocytes, NO is primarily synthesized by endothelial nitric oxide synthase (eNOS), in turn regulated by CaMKII. Protein phosphatases, which act in opposition to CaMKII, are believed to regulate cardiac gap junction communication.

Depressing either contractility or heart rate is a mechanism of action of many cardiac drugs, such as calcium-channel blockers.

| Drug          | Introduced–withdrawn | Mechanism of action with targets | Side effects on cardiac function | Mechanism of cardiac toxicity | References |
|---------------|----------------------|----------------------------------|---------------------------------|-------------------------------|------------|
| Orciprenaline | 1965–2011            | activation of ADRB2              | tachycardia, palpitations       | activation of ADRB2           | 92         |
| Prenylamine   | 1960s–1988           | blocking of MYLK2, CALM          | QT prolongation, sudden cardiac death, ventricular tachycardia, TdP | inhibition of I_Kr             | 85         |
| Probucol      | 1995–2009            | inductor of LDL catabolism        | QT prolongation, arrhythmias    | hERG trafficking inhibition   | 82         |

**Other agents**

- **Alogliptin** 2013–NA inhibition of DPP4 heart failure unknown 93
- **Clobutinol** 1963–2007 inhibition of GABA receptors QT prolongation inhibition of I_Kr 94
- **Rosiglitazone** 1994–NA activation of PPARG heart failure* unknown 95
- **Saxagliptin** 2009–NA inhibition of DPP4 heart failure unknown 96

TdP, torsade de pointes.

*Australia approved.

*Available only under a restricted distribution program.

*EMA approved only.

*Removed from the US market.

*FDA lifted restrictions for rosiglitazone and confirmed its safety.
that bind to L-type calcium channels and beta blockers that block beta adrenoceptors. Cardiac glycosides, which inhibit the Na⁺/K⁺ pump, can also depress heart rate, despite their well-known positive inotropic effects. The safe administration of cardiac glycosides is regarded as a difficult task because of their narrow safety margins, and the most potent inotropic agents generally have the lowest toxic-to-therapeutic ratios. However, some medications have been reported to disrupt contractility on other levels. The destabilization of the homeostatic calcium system has been proposed as the cardiotoxic mechanism of proton pump inhibitors. These have been suggested to inhibit dimethylarginine dimethylaminohydrolase (DDAH), an enzyme responsible for eliminating asymmetric dimethylarginine (ADMA), resulting in excess of ADMA impeding NO synthesis. Similarly, antineoplastic agents such as tyrosine kinases have been linked to upregulated CaMKII expression and activity.

**Mitochondrial toxicity**

Mitochondria play an important role in cardiac function, mainly by satisfying the immense energy requirements of contraction. As such, failure to replace malfunctioning mitochondria is highly injurious. Altered cardiac metabolism has been linked to cardiac disease development, such as ischemia, and conditions that increase the risk thereof, such as diabetes. Further demonstrating their association, contractility and the mitochondrial fusion-fission system were recently shown to be closely coupled (Figure 3): the fusion-fission cycle depends on calcium...
homeostasis, and fusion-fission abnormalities can lead to aberrant contraction.\cite{128}

As a by-product of their metabolic function, mitochondria produce reactive oxygen species (ROS) that, as shown in Figure 3, play an important role in proapoptotic signaling.\cite{128} ROS also engage dynamically in the mitochondrial fusion-fission cycle to respond to environmental stressors. Although mitochondrial fusion and fission help to reduce cellular stress under mild environmental stressors, these processes can also result in apoptosis and tissue necrosis in response to extreme stressors.\cite{129}

**Figure 3. Overview of mechanisms of cardiotoxicity**
Abnormalities in action potential duration or conduction velocity are associated with a direct block of ionic currents or inhibition of their trafficking from nucleus to cell membrane. Multiple pathways can trigger apoptosis, including VEGFR or EGFR inhibition (cardiomyocyte survival), PDGF inhibition (compensatory stress response), DR-induced TNF signaling activation, mitochondrial damage, or elevated ROS levels. α-Adr, VEGFR signaling, or eNOS inhibition affects calcium cycling. AMPK signaling inhibition affects both the mitochondrial fusion-fission cycle and the production of ATP. Serotonin-induced activation of the TGF-β pathway is primarily linked to cardiac fibrosis induction. I_{Kr}, rapid delayed rectifier current; I_{Na}, inward sodium current; I_{NaL}, late inward sodium current; I_{CaL}, L-type calcium current; α-Adr, alpha-adrenergic receptor; VEGFR, vascular endothelial growth factor receptor; EGFR, epidermal growth factor receptor; DRs, death receptors; PDGF, platelet-derived growth factor; 5-HT2β, 5-hydroxytryptamine receptor (serotonin receptor 2B); TNF, tumor necrosis factor; TGF-β, transforming growth factor beta; ROS, reactive oxygen species; CaMKII, calcium/calmodulin-dependent protein kinase II; AMPK, AMP-activated protein kinase; ATP, adenosine triphosphate.
Several pharmaceutical agents have been found to produce or facilitate mitochondrial toxicity, including in the heart. These inimical drugs span multiple classes, including anthracyclines, antivirals, antidepressants, and local anesthetics. The mitochondrial toxicity of anthracyclines is primarily linked to the inhibition of their direct target, topoisomerase (DNA) II beta (TOP2B), required for mitochondrial DNA replication. Antiretroviral drugs, often used to treat HIV, directly target and inhibit reverse transcriptase. However, antiretrovirals have been found to also inhibit mitochondrial DNA polymerase gamma (DNA Pol-gamma), depleting mitochondrial DNA and disrupting mitochondrial function. Moreover, anti-HIV therapies have also been shown to inhibit the mitochondrial fusion-fission cycle. Local anesthetics have been suggested to interact with phospholipids on the mitochondrial membrane, which often result in increased membrane permeability, electron transport chain disruption, and calcium accumulation.

**Growth factors and cytokine signaling**

Growth factors and cytokines are biologically active molecules that act directly on many cellular functions, such as adhesion, proliferation, and migration. Consequently, growth factor and cytokine signaling broadly affect tissue and organ function (Figure 3, top right).

Vascular endothelial growth factor (VEGF) is a signal protein responsible for the regulation of vascular formation, angiogenesis, cardiomyocyte development and proliferation, and myocardial regeneration. VEGF is also a major antiapoptotic factor that promotes cardiomyocyte survival in response to environmental stress or disease. Because angiogenesis is closely related to neoplastic metastasis and malignancy, controlling angiogenesis via inhibition of VEGF signaling is an attractive target. However, VEGF-inhibitory therapies are known to produce many adverse side effects, including cardiotoxicity. Closely related to VEGF, the platelet-derived growth factor (PDGF) is also key in myocardial development, in the angiogenic cardiovascular compensatory stress response, and in cardiac fibrosis. Inhibition of PDGF by sunitinib has been linked to its cardiotoxicity.

The epidermal growth factor receptor (EGFR) belongs to the epidermal growth factor (EGF) family of protein kinases, whose members include HER2, HER3, and HER4, and is essential to almost every known cellular process. HER2 is particularly crucial for cardiomyocyte differentiation and embryonic cardiac development. EGFR signaling is antiapoptotic, indicating it could lead to uncontrolled growth or intensified oncogenesis. Sufficient evidence suggests that EGF-activated VEGF signaling may enable the regulation of both angiogenesis and eNOS signaling. Taking these factors together, targeting EGFR to inhibit neoplastic growth has become an attractive avenue for potential antineoplastic therapies. Unfortunately, EGFR inhibitors, such as lapatinib or trastuzumab, have recently been linked to adverse cardiac effects. Activation of AMP-activated protein kinase (AMPK), which controls cellular energy and survival homeostasis and is required for mitochondrial fission in response to stress, could underlie the relatively low toxicity rate of lapatinib compared with the myocardial metabolism disruption associated to AMPK attenuation by other tyrosine kinase inhibitors.

**Main classes of drugs causing clinical cardiotoxicity**

**Antineoplastic agents**

Although significant improvements have arisen in recent years in chemotherapy safety, cardiovascular damage remains one of the most common adverse side effects of antineoplastic agents,
often resulting in diminished life expectancy for cancer patients. Two types of chemotherapy-induced cardiotoxicity have been established: irreversible (type I) and reversible (type II), respectively characterized by cellular damage and dysfunction.

### Antimitotics

**Anthracyclines.** Anthracyclines have been shown to be effective for the widest range of antineoplastic applications. They have four mechanisms of action by which they target actively proliferating neoplastic cells: DNA-RNA intercalation, TOP2B inhibition, iron-mediated generation of free radicals, and induction of the eviction of histone from chromatin.24

The cumulative and dose-related cardiotoxicities of anthracyclines are primarily linked to ROS formation, mitochondrial dysfunction, and cardiomyocyte apoptosis (Figure 3). Doxorubicin, a member of this class of agents, also has been shown to upregulate the expression of tumor necrosis factor (TNF)-mediated death receptors, involved in apoptosis in cardiomyocytes derived from induced pluripotent stem cells.21 Although cumulative cardiotoxicity is frequent among anthracyclines, the manufacturers of several claim no evidence of induced cardiotoxicity. For example, this is the case with amrubicin, approved by the Food and Drug Administration (FDA) of the United States of America, and marketed as Calsed in 2011 for lung cancer treatment.

**Antimetabolites.** Antimetabolites suppress the division of potentially cancerous, quickly dividing cells via interference with DNA replication. Because of their mechanism of action, their most frequent side effects are observed in highly proliferative tissues, such as the gastrointestinal tract, skin, or hair. Although less common, if cardiotoxicity arises, it generally does so within a week, with severity ranging from symptomatic arrhythmias to sudden cardiac death.9 The proposed mechanisms include multifactorial effects on the cardiovascular system: for example, 5-fluorouracil and cisplatin activate thromboxane A2 (TXA2) formation and platelet aggregation, potentially leading to cardiac remodeling and ischemia.146,147 Both drugs are also known to cause electrolyte imbalances, which play an important role in gastrointestinal toxicity.148,149 and are believed to be involved in their cardiotoxicity.149 Cytarabine is another antimetabolite with known cardiotoxicity;17,18 however, an understanding of its cardiotoxic mechanisms is still lacking.

**Antitubulins.** Vinca alkaloids and taxanes eliminate tumors by binding to microtubules. Like anthracyclines and antimetabolites, they target cell division and are primarily linked to gastrointestinal toxicity, although several antitubulins have been connected to specific adverse cardiac events. For example, this is the case with vinblastine, additionally associated with myocardial ischemia and infarction.36 Similarly, paclitaxel and docetaxel have been linked with bradycardia, ischemia, and heart failure.22 One of their proposed cardiotoxic mechanisms involves the inhibition of actively proliferating cardiac endothelial cells.150 However, given the sequential or combinatorial nature of cancer treatment, tubulin inhibitors are frequently administered after anthracyclines, which are often involved in cardiovascular adverse events. Therefore, the precise cardiotoxic role of tubulin inhibitors remains open for debate.

**Tyrosine kinase inhibitors**

Rather than targeting proliferating tissues, tyrosine kinase inhibitors exert their action by inhibiting tyrosine kinases as main enzymes responsible for the activation of signaling cascades in the synthesis of proteins. Despite reduced rates of side toxicity, some tyrosine kinase inhibitors have been associated with cardiovascular system damage. Cardiotoxicity is primarily linked to inhibition of major signaling pathways responsible for cardiomyocyte survival and maintenance, such as in the case of sorafenib or vandetanib, which are VEGF signaling inhibitors.138 However, lapatinib, an EGFR signaling inhibitor, presents low cardiotoxicity rates. As previously mentioned, this presumably results from its activation of the AMPK signaling pathway (Figure 3), which mobilizes cardiomyocytes and increases ATP synthesis and storage.35 In contrast, the tyrosine kinase inhibitor sunitinib, whose targets include vascular endothelial growth factor receptor (VEGFR), also inhibits the AMPK signaling pathway and potentially inhibits energy metabolism and PDGF signaling (Figure 3), all involved in the cardiomyocyte mechanical stress response.138,32 Different cardiotoxic mechanisms have been proposed for other tyrosine kinase inhibitors. Imatinib inhibits the chimeric oncogene bcr-abl, the protein constructed by the fusion of a breakpoint cluster region (bcr) with an Abelson tyrosine kinase (abl). Its cardiotoxicity is primarily linked to the release of B cell lymphoma 2 (Bcl-2) proteins, which cause mitochondrial damage.138 Interestingly, imatinib can inhibit the proliferation and apoptosis of neoplastic cells via hERG inhibition. Sunitinib and imatinib have demonstrated the ability to activate CaMKII expression and activity in vitro but without affecting myocardial contractility.125 In addition, sunitinib and imatinib induce high ROS levels (see also Figure 3), leading to reduced cell viability.151 Other bcr-abl inhibitors, such as dasatinib and nilotinib, are also known to induce cardiac adverse events,21 presumably linked to VEGF signaling inhibition.102

**Monoclonal antibodies**

Monoclonal antibodies, identical to antibodies produced by the immune system, specifically bind to extracellular and cell surface proteins, activating cellular apoptosis and blocking tumor proliferation. The adverse effects of this class of agents are primarily linked to their targets. HER2 inhibition by monoclonal antibodies is principally associated with cardiac dysfunction.33 Trastuzumab, a vascular endothelial growth factor A (VEGFA) inhibitor, is also known to downregulate Neuregulin-1, a signaling molecule in cardiac homeostasis and development.34 Its most common side effect is hypertension, but myocardial infarction may also occur.14 Bevacizumab, another monoclonal antibody, also negatively affects the coagulation system, probably because of its VEGF inhibition effects.13

**HDAC inhibitors**

HDACs are a class of enzymes that remove acetyl groups from an amino acid on a histone. HDAC inhibitors, used for neurological disease, have recently been proposed as a powerful new class of antineoplastic agents. However, growing concern regarding their cardiac safety has slowed their progress into clinical trials. For example, romidepsin, approved for clinical use in 2009, has been suggested to produce diverse cardiac adverse effects, including QT prolongation, torsade de pointes arrhythmias, and sudden cardiac death.153 Its cardiac adverse events are primarily linked to hERG trafficking inhibition rather than direct channel block.114 To date, 17 HDAC inhibitors exist, classically divided into 4 classes. However, cardiotoxicity is not class
specific. HDAC inhibitors of classes I, II, and IV are generally used as antineoplastics, whereas class III (known as sirtuins) could potentially be used as a cardioprotective agent by mainly reducing the risk of thrombosis, atherosclerosis, and endothelial dysfunction.\textsuperscript{154}

**Other antineoplastic agents**

Bortezomib is a proteasome inhibitor approved for myeloma treatment that inhibits the ability of malignant cells to escape apoptosis. Potential side effects include neutropenia, thrombocytopenia, and cardiotoxicity. Cardiac adverse events are considered reversible; however, bortezomib has been reported to cause arrhythmias and to even lead to heart failure.\textsuperscript{14,15}

Cardiotoxicity is linked to its primary target, the ubiquitin-proteasome system, which is essential for cardiomyocyte and mitochondrial function and controls hERG trafficking.\textsuperscript{155}

Recent reports have also raised concerns over the cardiac safety of immune checkpoint inhibitors, newer and highly effective anticancer therapies.\textsuperscript{35,26} Given their target, checkpoint inhibitors have been mainly associated with immune-related complications, such in the case of vitiligo.\textsuperscript{156} Lethal myocarditis has also been reported, although the underlying cardiotoxic mechanism remains unknown.

Used in leukemia, arsenic trioxide is another example of an anticancer drug with undesired cardiac complications, such as ventricular and supraventricular tachycardias.\textsuperscript{11,12} Its hERG trafficking inhibition (Figure 4) results in $I_{Ko}$ deficiency and action potential prolongation in both animal and human ventricular cells.\textsuperscript{157}

**CNS agents**

The electrophysiological function of both myocardial and nervous tissues requires the propagation of action potentials, a process triggered by external and intracellular mechanisms and involving the depolarization and repolarization of cellular membranes. Given the similarities in electrophysiology, CNS agents that target neuronal electrophysiology can also affect cardiac tissue. Consequently, drugs that cause neurotoxicity may also result in cardiotoxicity, although neurotoxicity is typically exhibited at lower doses.\textsuperscript{158} Other CNS agents have alternative mechanisms of cardiotoxicity that do not involve alterations of the electrophysiology.

**Local anesthetics**

Both heart and nervous tissues depend on sodium channels for action potential triggering. Local anesthetics frequently block sodium channels (Figure 3, top left) and therefore directly affecting both systems. The most cardiotoxic and neurotoxic local anesthetic is cocaine, first used in 1884.\textsuperscript{45} The next generation of local anesthetics, such as bupivacaine and lidocaine, was intentionally developed to overcome this toxicity. However, clinical evaluations demonstrated that bupivacaine (markedly more cardiotoxic than other local anesthetics) causes hemodynamic and electrophysiological disturbance, which may result in hypoxia, arrhythmia, and even cardiac arrest. Lidocaine and ropivacaine have also been shown to cause dose-dependent adverse cardiac reactions.\textsuperscript{31,154} A hypothesized mechanism of cardiotoxicity involves interactions between local anesthetics and mitochondrial membranes (Figure 3) by increasing the permeability of cardioliopin, thus interrupting function and potentially inducing apoptosis.\textsuperscript{134}

**Antidepressants**

Available evidence emphasizes antidepressants as a CNS class with significant cardiovascular side effects. Indeed, several antidepressants were withdrawn from the market or restricted for use because of cardiac adverse reactions. Tricyclic antidepressants and neuroleptics directly interact with sodium, calcium, and potassium channels (Figure 3, top left) and can cause fatal arrhythmias and hypotension in overdose.\textsuperscript{159} The next generation of antidepressants is considered of lower risk, with fewer cardiac adverse effects reported, but they too inhibit cardiac sodium, calcium, and potassium channels.\textsuperscript{160} As an example, the selective serotonin inhibitor fluoxetine inhibits the L-type calcium current ($I_{CaL}$) and $I_{Ko}$ in addition to its primary targets. It has also been shown to disrupt hERG trafficking.\textsuperscript{112} and long-term use may result in mild bradycardia. The potentially more arrhythmic venlafaxine, another selective serotonin inhibitor, has been shown to block the inward sodium current ($I_{Na}$) in both humans and animals.\textsuperscript{72,161}

**Antipsychotics**

Psychiatric disorders are known to be accompanied by an increased risk of cardiovascular disease.\textsuperscript{162} In addition, many antipsychotics have been found to cause QT prolongation and cardiotoxicity.\textsuperscript{37} Clozapine, a highly effective treatment for schizophrenia, has been linked to serious complications such as myocarditis, an inflammatory cardiac muscle disease.\textsuperscript{43,44} Therefore, it is generally considered the last resort if other antipsychotics are ineffective. However, the mechanism underlying clozapine-induced myocarditis is unknown. The antipsychotic sertindole was removed from market in 1998 due to QT prolongation and sudden cardiac death, primarily because of its high-affinity $I_{Kr}$ block.\textsuperscript{163} However, it was relaunched on the European market in 2005 with required cardiac monitoring. Other antipsychotics for schizophrenia and bipolar disorder, such as thioridazine, ziprasidone, and haloperidol, can lead to QT prolongation, torsade de points arrhythmias, or even sudden cardiac death.\textsuperscript{51} Ziprasidone has been shown to block $I_{Kr}$, thioridazine blocks both late inward sodium current ($I_{NaL}$) and $I_{Ko}$, and haloperidol blocks $I_{Kr}$, $I_{Na}$, and $I_{CaL}$ without affecting $I_{NaL}$.\textsuperscript{160,164} Ziprasidone and clozapine also have been found to block alpha-adrenergic receptors,\textsuperscript{165} involved in calcium cycling regulation in cardiomyocytes.

**Neurodegenerative disease agents**

At present, neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease are incurable, attracting immense interest in the development of prospective therapies. Among them is pergolide, a dopamine receptor antagonist with potential application in Parkinson’s disease. However, pergolide has been associated with the emergence of fibrosis in multiple tissues, including the heart.\textsuperscript{6} This is believed to stem from pergolide activating serotonin HTR2B receptors (Figure 3, right), inducing the transforming growth factor beta (TGF-$\beta$) pathway.\textsuperscript{55,166} Pergolide use was consequently restricted because of increased risk of fibrotic valvular heart disease.

**Other CNS agents**

Further applications of CNS agents include their use in pain or appetite control. Methysergide and ergotamine, serotonin 5-hydroxytryptamine (5-HT) receptor inhibitors (Figure 3, right side) used for migraines, are known to share adverse cardiac effects...
with pergolide and to cause cardiac fibrosis. In addition, several appetite suppressants, including dexfenfluramine, fenfluramine and phentermine, chlorphentermine, and benfluorex, were lifted from the market due to cardiac fibrosis. The primary mechanism of fibrosis induction is believed to involve the activation of the TGF-β pathway through 5-HT₂ receptor stimulation. Another discontinued appetite suppressant drug, sibutramine, was linked to myocardiad infarction. Its underlying mechanism remains undescribed, but in vitro experiments showed that sibutramine blocks the Iᵦₛ channel.

Opioid analgesics also have been shown to affect cardiac electrophysiology. This led to the withdrawal of levomethadyl acetate in 2001 from the European market and propoxyphene in 2010. Although the FDA reported that levomethadyl acetate had no cardiotoxic effect, it was also lifted from the US market in 2003.

Genitourinary system agents
Muscarinic receptor antagonists are a class of drugs approved for treatment of incontinence. Although generally considered safe, they have a well-known potential to affect cardiac function and may increase heart rate, prolong QT, and increase cardiovascular risk when used concomitantly with other medications. Especially relevant within this class, terodiline, a muscarinic receptor antagonist, was withdrawn from the market due to serious cardiac side effects, such as torsade de points and even cardiac arrest among older people. The toxicity of terodiline is linked to the inhibition of the hERG-encoded channel and the disruption of calcium cycling, with its cardiotoxic effects depending on concentration and genetic background. The withdrawal of terodiline has since raised concerns about potential cardiac adverse reactions by the whole group of muscarinic receptor antagonists.

Gastrointestinal agents
As in the heart and nervous tissues, the function of the gastrointestinal tract is heavily controlled by cellular electrophysiology. 5-HT₄ receptors, located in the alimentary tract, heart, or CNS, can be pharmacologically modulated to control the release of neurotransmitters. Cisapride, a drug that increases motility in the upper gastrointestinal tract, was designed to block serotonin 5-HT₄, but it also inhibits hERG, in addition to 5-HT₂A and 5-HT₃A serotonin receptors. Its marked hERG inhibition produced cardiac arrhythmias and torsade de points, leading to its withdrawal from the market in most countries. Tegaserod, a nonsel ective 5-HT₄ inhibitor, was also withdrawn by the FDA in 2007 despite absence of reports showing hERG channel inhibition. New versions of selective 5-HT₄ blockers, such as clebopride and mosapride, are considered cardiac safe.

Other types of receptors are also present in the gastrointestinal system. For example, loperamide, an opioid antagonist approved for treating diarrhea symptoms, blocks the mu-opioid receptor. Loperamide has also been shown to inhibit voltage-gated calcium channels and may produce cardiotoxic effects in humans. In 2016, the FDA issued an announcement indicating that high doses of loperamide, or its misuse, could cause serious cardiac adverse events, including lethal heart attacks.

Proton pump inhibitors, such as omeprazole, are another class of gastrointestinal agents labeled as cardiotoxic. Although a direct connection between omeprazole and cardiotoxicity has never been fully established and the mechanism of action remains unknown, it may arise because of ADMA production, which interferes with NO synthesis (Figure 3) and accelerates endothelial cellular senescence.

Antihistamines
H1 antihistamines reduce allergic responses by blocking histamine H1 receptors on the cell surface. The biological role of histamines includes participation in the immune response to pathogens and allergens by increasing capillary permeability. Within the cardiovascular system, the stimulation of H1 receptors results in the constriction of coronary blood vessels, inducing a positive chronotropic effect. However, two second-generation antihistamines, terfenadine and astemizole, were withdrawn from the market due to QT prolongation and torsade de points linked to their direct block of Iᵦₛ. Diphenhydramine, the first antihistamine introduced to the market, also demonstrated a QT prolongation signature upon overdose.

Anti-inflammatory agents
Nonsteroidal anti-inflammatory drugs (NSAIDs) are a broad class of agents that target one or both prostaglandin synthases (COX-1 and COX-2) and hence display anti-inflammatory properties. NSAID side toxicities, such as gastrointestinal toxicity, primarily result from COX-1 inhibition, and new generations of NSAIDs selectively target COX-2. However, both selective COX-2 inhibitors and high doses of nonselective COX inhibitors can display cardiotoxic side effects. In 2004, the FDA withdrew the COX-2 inhibitor rofecoxib, one of the most widely used drugs ever withdrawn from the market. Although its significant cardiotoxicity seemed to be linked to its unique metabolism, in 2007, the FDA issued a nonapproval letter for the selective COX-2 inhibitor etoricoxib due to cardiotoxic concerns. In response to these concerns, the FDA strengthened the safety warning on NSAID labels in 2015. Long-term administration of both selective COX-2 inhibitors, such as diclofenac, and nonselective COX-1/COX-2 inhibitors, such as ibuprofen, naproxen, and indomethacin, has been shown to increase the risk of cardiac arrest.

The cardiotoxic mechanism of selective COX-2 inhibitors is primarily linked to blocking prostacyclin synthase without affecting TXA₂ synthesis, leading to an increased risk of thrombosis. In contrast to antimetabolites that induce TXA₂ formation, increasing the risk of ischemia, evidence suggests that COX-2 inhibitors decrease the risk of ischemia because of their ability to reduce inflammation.

Anti-infective agents
Anti-infective agents are compounds with selective toxicity against pathogens, such as bacteria, viruses, or other microorganisms. Anti-infective agents vary by the mechanism of action and side effects.

Antibiotics
Antibiotics, among the most prescribed drugs worldwide, primarily disrupt the bioactive processes of pathogens, such as cell wall construction, protein and nucleic acid metabolism, and repair. Because human cells share some functions with prokaryotic pathogens, some antibiotics (such as anthracyclines)
are also used as antineoplastic agents. The cardiotoxicity of cytostatic antibiotic agents has been discussed. Macrolides, which target bacterial protein synthesis via inhibition of prokaryotic ribosomal subunits and are widely used for respiratory infections, have also been shown to block hERG. Macrolides such as erythromycin, azithromycin, and clarithromycin are considered arrhythmogenic. It has also been shown that macrolides cause mitochondrial toxicity (Figure 3) by inhibiting protein synthesis in mitochondria. Fluoroquinolones are another group of antibiotics that can affect hERG and cause torsade de pointes. Because of this effect, use of fluoroquinolones such as grepafloxacin and sparfloxacin was discontinued.

**Antivirals**

The design of safe antivirals is complicated, because viruses use host cell structures to replicate. A major concern of antiviral therapy is mitochondrial toxicity in liver, skeletal muscle, and heart tissues. Azidothymidine, an antiretroviral HIV treatment, has been shown to induce mitochondrial dysfunction, leading to mitochondrial fragmentation and an impaired fusion-fission cycle (Figure 4), causing action potential prolongation in both animal and human cells.

**Other anti-infective agents**

Pentamidine, used to treat leishmaniasis, trypanosomiasis, and pneumonia, has been associated with QT prolongation and ventricular arrhythmias in intravenous treatment. In vitro experiments showed that despite being a poor direct blocker of $\mathrm{I_{K}}$, it affects hERG trafficking (Figure 4), causing action potential prolongation in both animal and human cells.

**Cardiovascular agents**

Paradoxically, the worsening of arrhythmic risk is a serious side effect of some antiarrhythmic agents. Several highly potent drugs were lifted from the market or restricted in use because of proarrrhythmic effects, including dofetilide and encainide. Some nonselective calcium blockers, such as lidoflazine and prenylamine, were also suspended because of their life-threatening QT prolongation. This side effect is primarily linked to their high-affinity block of hERG channels. Bufomedil, an alpha-adrenoceptor antagonist, was withdrawn from the European market due to its unfavorable cardiac safety profile. The selective beta-adrenoceptor blocker orciprenaline was removed from the market due to life-threatening cardiac side effects.

The efficacy and safety of cardiovascular agents have been investigated by landmark clinical trials, such as the Cardiac Arrhythmia Suppression Trial (CAST) focused on the class I antiarrhythmic agents encainide and flecainide. This study reported increased mortality rates caused by arrhythmia and myocardial infarction shock in patients treated with flecainide and encainide compared with placebo groups. Follow-up studies suggested existing structural heart disease, with ischemic and electrical instability present, to be the major risk factor for developing adverse reactions to flecainide. Later, the Survival with Oral d-Sotalol (SWORD) study raised concerns regarding the use of class III antiarrhythmic agents and demonstrated post-myocardial infarction patients at a higher risk of developing drug-induced arrhythmias. The same was shown for dronedarone, another class III antiarrhythmic, in the Antiarrrhythmic Trial with Dronedarone in Moderate to Severe CHF Evaluating Morbidity Decrease (ANDROMEDA) and in the Permanent Atrial Fibrillation Outcome Study Using Dronedarone on Top of Standard Therapy (PALLAS).

The cholesterol-lowering agent probucol, despite association with QT prolongation and arrhythmias, was discontinued from the US market due to lack of efficacy against coronary artery disease. Probucol affects hERG trafficking (Figure 4), and it was shown to cause electrophysiological abnormalities in neonatal rat ventricular cardiomyocytes.

The antihypertension drug mibefradil is another example of a cardiovascular drug removed from the market, in 1998, because of safety concerns. Mibefradil blocks calcium channels and was shown to cause abnormal QT prolongation.

**Other agents**

A negative effect of antidiabetic drugs is their increased risk of heart failure, which has been confirmed in different studies. Considering such a risk, the European Medicines Agency (EMA) and FDA issued restrictions in 2010 for different drugs containing rosiglitazone, a thiazolidinedione-class antiarrhythmic drug. After a thorough examination of large clinical trials, the FDA removed those restrictions and eliminated the risk evaluation and mitigation strategy for rosiglitazone. Concerns regarding the safety of saxagliptin and alogliptin were also raised.

In 2007, the cough suppressant clobutinol was lifted from the market by its manufacturer due to risk of QT prolongation. Animal experiments suggested that clobutinol inhibits hERG channels and can induce torsade de pointes.

**Conclusions**

In this review, we have presented a comprehensive discussion of drug-protein mechanisms underlying clinical drug-induced cardiotoxicity. This significantly broadens other studies by covering adverse effects and cardiotoxic mechanisms of cardiovascular, anticancer, CNS, genitourinary system, gastrointestinal, antithrombinic, anti-inflammatory, and anti-infective agents beyond their direct interactions with cardiac electrophysiology. As a result, we illustrate that many of these drug classes share modes of action on cardiac function and on adverse cardiac events, with cardiotoxicity frequently resulting from the simultaneous interruption of key myocardial functions and viabilities (mitochondrial dysfunction, inhibition of major signaling pathways responsible for cardiomyocyte survival and maintenance, fibrosis, NO synthesis, calcium cycling, and cellular trafficking).

Understanding of the mechanisms of drug-induced toxicity and differences in cardiac safety profiles of therapies is important for the development of new compounds and of safety assays for preclinical testing. In the clinical scenario, the drug-induced mechanisms leading to adverse cardiac events are generally considered multifactorial in origin, and they often remain poorly understood.
understood. Therefore, a refined understanding of the multifaceted components of cardiotoxicity can lead to the development of new cardioprotective agents, with the potential of reducing the manifestation and damage of otherwise-effective but risky drugs. As an exemplar, statins have been proposed to lower anthracycline-induced harm via a reduction of ROS signaling and regulation of TOP2B.\textsuperscript{182} Similarly, the activation of the AMPK pathway by lapatinib may underlie its lower cardiotoxicity compared with other tyrosine kinase inhibitors. Other AMPK activators, such as metformin, have been shown to be protective for several heart conditions.\textsuperscript{183} Nevertheless, it is important to remember that cardiotoxicity highly depends on exposure levels (especially overdose) and the duration of treatment; thus, only some of the discussed adverse effects may be involved in clinical practice. For clinical applications such as oncology treatments, the risk-benefit ratios often overpower the consequences of potential cardiotoxic events.

This review focuses on mechanisms of drug-induced cardiac adverse effects, centering its scope on drug-protein interactions. Although certain mechanisms of action, such as tyrosine kinase inhibition or mitochondrial damage, could affect other cell types in the organism, in this review, we have centered our efforts on summarizing their known clinical manifestations on cardiac side effects. Drug-drug and drug-food interactions are also known to promote adverse cardiovascular effects, usually linked to competition among enzymes participating in drug metabolism or alterations in drug metabolism.\textsuperscript{184,185} In addition, recent advances in the annotation of RNA-RNA interactions suggest they might be of even higher importance in cardiac disease, such as heart failure and hypertrophy.\textsuperscript{186,187}

All of these mechanisms of drug-induced cardiotoxicity constitute important and promising prospects for future research into drug discovery, safety pharmacology, and pharmacovigilance studies. Therefore, their integration as a priority into multi- and interdisciplinary approaches across academia, industry, and healthcare settings, for the complex characterization of human heart physiology,\textsuperscript{188,189} is expected to yield major advances for the analysis and prediction of adverse drug reactions and cardiotoxicity in humans, both in health and in disease.

ACKNOWLEDGMENTS

This work was funded by a British Heart Foundation (BHF) Intermediate Basic Science Fellowship (FS/17/22/32644 to A.B.-O.), a Wellcome Trust Fellowship in Basic Biomedical Sciences (214290/Z/18/Z to B.R.), an Infrastructure for Impact Award from the National Centre for Replacement Refinement and Reduction of Animals in Research (NC/P001076/1), and the Oxford BHF Centre of Research Excellence (RE/13/21/30181 and RE/13/2/30182).

AUTHOR CONTRIBUTIONS

P.M., B.R., and A.B.-O. conceived the study approach and planning. P.M. performed the literature review and wrote the manuscript. B.R. and A.B.-O. provided critical discussion. All authors revised and approved the final manuscript.

DECLARATION OF INTERESTS

The authors declare no competing interests.

REFERENCES

1. Ferri, N., Siegl, P., Corsini, A., Herrmann, J., Lerman, A., and Benghuzzi, R. (2013). Drug attrition during pre-clinical and clinical development: understanding and managing drug-induced cardiotoxicity. Pharmacol. Ther. 138, 470–484.

2. Ford, G.A., Wood, S.M., and Daly, A.K. (2000). CYP2D6 and CYP2C19 genotypes of patients with terodiline cardiotoxicity identified through the yellow card system. Br. J. Clin. Pharmacol. 50, 77–80.

3. Garcia-Pavia, P., Kim, Y., Restrepo-Cordoba, M.A., Lunde, I.G., Waki-moto, H., Smith, A.M., Toepfer, C.N., Getz, K., Gorham, J., Patel, P., et al. (2019). Genetic Variants Associated With Cancer Therapy-Induced Cardiomyopathy. Circulation 140, 31–41.

4. Sloan, J.A., Goldberg, R.M., Sargent, D.J., Vargas-Chanes, D., Nair, S., Cha, S.S., Novotny, P.J., Poon, M.A., O’Connell, M.J., and Loprinzi, C.L. (2002). Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer. J. Clin. Oncol. 20, 1491–1498.

5. Zhao, L., and Zhang, B. (2017). Doxorubicin induces cardiotoxicity through upregulation of death receptors mediated apoptosis in cardio-myocytes. Sci. Rep. 7, 44735.

6. Waller, E.A., and Kaplan, J. (2006). Pergolide-associated valvular heart disease. Compr. Ther. 32, 94–101.

7. Albert, R.K., and Schuller, J.L.: COPD Clinical Research Network (2014). Macrolide antibiotics and the risk of cardiac arrhythmias. Am. J. Respir. Crit. Care Med. 189, 1173–1180.

8. Nomura, R., Sato, T., Sato, Y., Medin, J.A., Kushimoto, S., and Yanagi-sawa, T. (2017). Azidothymidine-triphosphate impairs mitochondrial dynamics by disrupting the quality control system. Redox Biol. 13, 407–417.

9. Polk, A., Vaage-Nilsen, M., Vistisen, K., and Nielsen, D.L. (2013). Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: a systematic review of incidence, manifestations and predisposing factors. Cancer Treat. Rev. 39, 974–984.

10. Rateesh, S., Luis, S.A., Luis, C.R., Hughes, B., and Nicolae, M. (2014). Myocardial infarction secondary to 5-fluorouracil: not an absolute contraindication to rechallenge? Int. J. Cardiol. 172, e331–e333.

11. Ducas, R.A., Setfie, M.D., Ducas, J., and Seifer, C. (2011). Monomorphic ventricular tachycardia caused by arsenic trioxide therapy for acute promyelocytic leukaemia. J. R. Coll. Physicians Edinb. 41, 117–118.

12. Onishi, K., Yoshida, H., Shigeno, K., Nakamura, S., Fujisawa, S., Naito, K., Shinjo, K., Fujita, Y., Matsui, H., Takeshita, A., et al. (2000). Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukaemia. Ann. Intern. Med. 133, 881–885.

13. Economidou, P., Kotsakia, A., Kapiris, I., and Kentepozidis, N. (2015). Cancer therapy and cardiovascular risk: focus on bevacizumab. Cancer Manag. Res. 7, 133–143.

14. Mesehea, M.G., Kolade, V.O., and Attia, M.N. (2015). Partially reversible bortezomib-induced cardiotoxicity: an unusual cause of acute cardiomyopathy. J. Community Hosp. Intern. Med. Perspect. 5, 28982.

15. Xiao, Y., Yin, J., Wei, J., and Shang, Z. (2014). Incidence and risk of cardiototoxicity associated with bortezomib in the treatment of cancer: a systematic review and meta-analysis. PLoS ONE 9, e87671.

16. Fukunaga, T., Soejima, H., Sugamura, K., Kojima, S., Sugiyama, S., Sakamoto, T., Yoshimura, M., Tanoue, T., Kageshita, T., Ono, T., and Ogawa, H. (2006). Acute myocardial infarction induced by cisplatin-based combination chemotherapy for malignant leukemia: a case report. J. Cardiol. 47, 191–195.

17. Conrad, M.E. (1992). Cytarabine and cardiac failure. Am. J. Hematol. 41, 143–144.

18. Wayangankar, S.A., Patel, B.C., Parekh, H.D., Holter, J.L., and Lazzara, R. (2015). High-dose cytosine arabinoside-induced symptomatic brady-cardia. J. Cardiovasc. Med. (Hagerstown) 16 (Suppl 1), S38–S41.
59. Eroglu, E., Gencici, G., Bayrak, F., Kalkan, A.K., and Degertekin, M. (2009). Acute myocardial infarction in a 24 year-old man possibly associated with sibutramine use. Int. J. Cardiol. 137, e43–e45.

60. James, W.P.T., Caterson, I.D., Coutinho, W., Finer, N., Van Gaal, L.F., Maggioni, A.P., Torp-Pedersen, C., Sharma, A.M., Shepherd, G.M., Rode, R.A., and Renz, C.L.; SCOUT Investigators (2010). Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N. Engl. J. Med. 363, 905–917.

61. Howell, C., Wilson, A.D., and Waring, W.S. (2007). Cardiovascular toxicity due to venlafaxine poisoning in adults: a review of 235 consecutive cases. Br. J. Clin. Pharmacol. 64, 192–197.

62. Johnson, E.M., Whyte, E., Mulsant, B.H., Pollock, B.G., Weber, E., Begley, A.E., and Reynolds, C.F. (2006). Cardiovascular changes associated with venlafaxine in the treatment of late-life depression. Am. J. Geriatr. Psychiatry 14, 796–802.

63. Quigley, E.M.M. (2017). Prokinetics in the Management of Functional Gastrointestinal Disorders. Curr. Gastroenterol. Rep. 19, 53.

64. Upadhyay, A., Bodar, V., Malekzadegan, M., Singh, S., Frumkin, W., Mangla, A., and Doahi, K. (2016). Loperamide Induced Life Threatening Ventricular Arrhythmia. Case Rep. Cardiol. 2016, 5040176.

65. Swank, K.A., Wu, E., Kortepeter, C., McAninch, J., and Levin, R.L. (2017). Food and Drug Administration (2007). Drug Safety and Availability—Zetakaze: a retrospective cohort study. BMJ Open 7, e013398.

66. Jo, S.-H., Hong, H.-K., Chong, S.H., Lee, H.S., and Choe, H. (2009). H(1) antihistamine drug promethazine directly blocks hERG K(+) channel. J. Pharmacol. Toxicol. Methods 68, 53–56.

67. Bishop, R.O., and Gaudry, P.L. (1989). Prolonged Q-T interval following astemizole overdose. Arch. Emerg. Med. 6, 63–65.

68. Thomas, S.H., Higham, P.D., Hartigan-Go, K., Kamali, F., Wood, P., Campbell, R.W., and Ford, G.A. (1995). Concentration dependent cardio-ototoxicity of terodiline in patients treated for urinary incontinence. Br. Heart J. 74, 53–56.

69. Stewart, D.A., Taylor, J., Ghosh, S., Macphee, G.J., Abdullah, I., McLennach, J.M., and Stott, D.J. (1992). Terodiline causes polymorphic ventricular tachycardia due to reduced heart rate and prolongation of QT interval. Eur. J. Clin. Pharmacol. 42, 577–580.

70. Jo, S.-H., Hong, H.-K., Chong, S.H., Lee, H.S., and Choe, H. (2009). H(1) antihistamine drug promethazine directly blocks HERG K(+) channel. Pharmacol. Res. 60, 429–437.

71. Bishop, R.O., and Gaudry, P.L. (1989). Prolonged Q-T interval following astemizole overdose. Arch. Emerg. Med. 6, 63–65.

72. Khalifa, M., Daleau, P., and Turgeon, J. (1999). Mechanism of sodium channel block by venlafaxine in guinea pig ventricular myocytes. J. Pharmacol. Exp. Ther. 291, 280–284.

73. Shah, A., Yousuf, T., Ziffra, J., Zaidi, A., and Raghuvir, R. (2015). Diphenhydramine and QT prolongation—A rare cardiac side effect of a drug used in common practice. J. Cardiol. Cases 12, 126–129.

74. Monahan, B.P., Ferguson, C.L., Killeavy, E.S., Lloyd, B.K., Troy, J., and Macdonald, E.M.; SCOUT Investigators (2010). Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N. Engl. J. Med. 363, 905–917.

75. Carr, A., and Cooper, D.A. (2000). Adverse effects of antiretroviral therapy. Lancet 356, 1423–1430.

76. Ray, V.A., Murray, K.T., Hall, K., Argobast, P.G., and Stein, C.M. (2012). Azithromycin and the risk of cardiovascular death. N. Engl. J. Med. 366, 1881–1890.

77. Berni, E., de Voogd, H., Halcox, J.P., Butler, C.C., Bannister, C.A., Jenkins-Jones, S., Jones, B., Ouwens, M., and Currie, C.J. (2017). Risk of cardiovascular events, arrhythmia and all-cause mortality associated with clarithromycin versus alternative antibiotics prescribed for respiratory tract infections: a retrospective cohort study. BMJ Open 7, e013398.
100. Mirams, G.R., Cui, Y., Sher, A., Fink, M., Cooper, J., Heath, B.M., McManus, E., Britton, O.J., Lu, H.R., Rohrbacher, J., Hermans, A.N., Galbraith, M.-J. (2014). Arsenic trioxide induces unfolded protein response in human colon cancer cells. Cell Reports, 7, 2457–2471.

101. Passini, E., Britton, O.J., Lu, H.R., Rohrbacher, J., Hermans, A.N., Galbraith, M.-J., Bueno-Orovio, A., and Rodriguez, B. (2017). Human in silico drug trials demonstrate higher accuracy than animal models in predicting clinical pro-arrhythmic cardioxotoxicity. Front. Physiol. 8, 668.

102. Britton, O.J., Bueno-Orovio, A., Virág, L., Varró, A., and Rodriguez, B. (2017). The electrogenic Na+/K+ pump is a key determinant of repolarization abnormality susceptibility in human ventricular cardiomyocytes: A population-based simulation study. Front. Physiol. 8, 278.

103. Turan, B., and Dhalla, S.N. (2014). Diabetic Cardiomyopathy (Springer Science & Business Media).

104. Ficker, E., Kuryashev, Y.A., Dennis, A.T., Obiero-Paz, C., Wang, L., Hawryluk, P., Wible, B.A., and Brown, A.M. (2004). Mechanisms of arsenic-induced prolongation of cardiac repolarization. Mol. Pharmacol. 66, 33–44.

105. Zhang, X., Yu, D., Geng, H., Li, F., Lv, L., Zhao, L., Yan, C., and Li, B. (2018). Dual effects of arsenic trioxide on tumor cells and the potential underlying mechanisms. Oncol. Lett. 16, 3812–3820.

106. Yu, D., Lv, L., Fang, L., Zhang, B., Wang, J., Zhan, G., Zhao, L., Zhao, X., and Li, B. (2017a). Inhibitory effects and mechanism of dithydroberine on hERG channels expressed in HEK293 cells. PLoS ONE 12, e0161823.

107. Zhang, K., Zhi, D., Huang, T., Gong, Y., Yan, M., Liu, C., Wei, T., Dong, Z., Li, B., and Yang, B. (2014). Berberine induces hERG channel deficiency through trafficking inhibition. Cell. Physiol. Biochem. 34, 691–702.

108. Weng, C.-Y., Chiu, S.-Y., Wang, L., Kou, M.-C., Wang, Y.-J., and Wu, M.-J. (2014). Arsenic trioxide induces unfolded protein response in vascular endothelial cells. Arch. Toxicol. 88, 213–226.

109. Wang, L., Wible, B.A., Wan, X., and Ficker, E. (2007). Cardiac glycosides as novel inhibitors of human ether-a-go-go-related gene channel trafficking. J. Pharmacol. Exp. Ther. 320, 525–534.

110. Apaja, P.M., Foo, B., Okiyoneda, T., Valinsky, W.C., Barriere, H., Atanasiu, R., Ficker, E., Lukacs, G.L., and Shrier, A. (2013). Ubiquitination-dependent quality control of hERG K+ channel with acquired and inherited conformational defect at the plasma membrane. Mol. Biol. Cell 24, 3787–3804.

111. Hubbi, M.E., Hu, H., Kshitz, Ahmed, I., Levchenko, A., and Semenza, G.L. (2013). Chaperone-mediated autophagy targets hypoxia-inducible factor-1α (HIF-1α) for lysosomal degradation. J. Biol. Chem. 288, 10703–10714.

112. Guo, J., Masaeki, H., Li, W., Xu, J., Luo, T., Shaw, J., Kirshenbaum, L.A., and Zhang, S. (2007). Identification of Ikr and its trafficking disruption induced by probeol in cultured neonatal rat cardiomyocytes. J. Pharmacol. Exp. Ther. 327, 911–920.
132. McGowan, J.V., Chung, R., Maulik, A., Piotrowska, I., Walker, J.M., and Yellen, D.M. (2017). Anthracycline Chemotherapy and Cardiotoxicity. Cardiovasc. Drugs Ther. 31, 63–75.

133. Lewis, W., Day, B.J., and Copeland, W.C. (2003). Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective. Nat. Rev. Drug Discov. 2, 812–822.

134. Tsuchiya, H., and Mizogami, M. (2013). Interaction of local anesthetics with biomembranes consisting of phospholipids and cholesterol: mechanistic and clinical implications for anesthetic and cardiotoxic effects. Anesthesiol. Res. Pract. 2013, 297141.

135. Taimeh, Z., Loughran, J., Birks, E.J., and Bolli, R. (2013). Vascular endothelial growth factor in heart failure. Nat. Rev. Cardiol. 10, 519–530.

136. Zhao, T., Zhao, W., Meng, W., Liu, C., Chen, Y., Gerling, I.C., Weber, K.T., Bhattacharya, S.K., Kumar, R., and Sun, Y. (2015). VEGF-C/VEGFR-3 pathway promotes myocyte hypertrophy and survival in the infarcted myocardium. Am. J. Transl. Res. 7, 697–709.

137. Quesada, A.R., and Medina, M.A. (2010). Angiogenesis in cancer: Therapeutic targets and angiogenesis inhibitors. In Angiogenesis & Therapeutic Targets In Cancer, M. Chatterjee, ed. (Bentham Science Publishers), pp. 45–67.

138. Chen, Z.I., and Ai, D.I. (2016). Cardiotoxicity associated with targeted cancer therapies. Mol. Clin. Oncol. 4, 675–681.

139. Bloomekatz, J., Singh, R., Prall, O.W., Dunn, A.C., Vaughan, M., Loo, C.-Y., Parent, J.-L. (2012). Thromboxane A2 modulates cisplatin-induced acute heart failure: a rare symptom of cisplatin cardiotoxicity: A case report. Oncol. Lett. 11, 2297–2299.

140. Chintalgattu, V., Ai, D., Langley, R.R., Zhang, J., Bankson, J.A., Shih, C.-M., and Roden, D.M. (2014). Screening for acute IKr block is insufficient to prevent torsades de pointes liability: role of late sodium current. Circulation 130, 224–234.

141. Iorio-Morin, C., Germain, P., Roy, S., Génier, S., Labrecque, P., and Parent, J.-L. (2012). Thromboxane A2 modulates cisplatin-induced apoptosis through a Siva1-dependent mechanism. Cell Death Differ. 19, 1347–1357.

142. Togna, G.I., Togna, A.R., Franconi, M., and Caprino, L. (2010). Cisplatin tubulin-binding drugs. Toxicol. Sci. 117, 144–151.

143. Woin, M., Feng, L., Shi, Y., Wang, J., Liu, Y., Li, F., and Li, B. (2017). Mechanisms of anthracycline cardiotoxicity associated with targeted cancer therapies. Mol. Clin. Oncol. 8, 2658–2668.

144. Toyama, E.Q., Herzig, S., Courchet, J., Lewis, T.L., Jr., Loson, O.C., Hellwig, K., Young, N.P., Chen, H., Polleux, F., Chan, D.C., et al. (2016). AMP-activated protein kinase mediates mitochondrial fission in response to energy stress. Science 351, 275–281.

145. Geisberg, C.A., and Sawyer, D.B. (2010). Mechanisms of anthracycline cardiotoxicity and strategies to decrease cardiac damage. Curr. Hypertens. Rep. 12, 404–410.

146. Arana, A., Margulis, A.V., McQuay, L.J., Ziemiecki, R., Bartsch, J.L., and Klastersky, J. (2016). Immune checkpoint inhibitors side effects and management. Immunotherapy 8, 799–807.

147. Andreani, M.H.K.R., and Thomas, S.H.L. (2005). Tricyclic antidepressant poisoning: cardiovascular toxicity. Toxicol. Rev. 24, 205–214.

148. Kourie, H.R., and Klasterky, J. (2013). Protective effects of sirtuins in cardiovascular diseases: from bench to bedside. Eur. Heart J. 38, 3404–3412.

149. Doherty, K.R., Talbert, D.R., Trusk, P.B., Moran, D.M., Shell, S.A., and Bacs, S. (2015). Structural and functional screening in human induced-pluripotent stem cell-derived cardiomyocytes accurately identifies cardiotoxicity of multiple drug types. Toxicol. Appl. Pharmacol. 285, 51–60.

150. Mosleh, J.J., and Deininger, M. (2015). Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia. J. Clin. Oncol. 33, 4210–4218.

151. Lancelotti, P., Zamorano, J.L., and Galderisi, M. (2016). Anticancer treatments and cardiotoxicity. Mechanisms, diagnostic and therapeutic interventions (Academic Press, Elsevier).

152. Winnik, S., Auwen, J., Sinclair, D.A., and Matter, C.M. (2015). Protective effects of sirtuins in cardiovascular diseases: from bench to bedside. Eur. Heart J. 38, 3404–3412.

153. Mosleh, J.J., and Deininger, M. (2015). Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia. J. Clin. Oncol. 33, 4210–4218.

154. Togna, G.I., Togna, A.R., Franconi, M., and Caprino, L. (2010). Cisplatin tubulin-binding drugs. Toxicol. Sci. 117, 144–151.
Stanghellini, V. (2012). Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders. Aliment. Pharmacol. Ther. 35, 745–767.

170. Hazarika, S., and Annex, B.H. (2016). Can Endothelial Injury Provide the Passage to Explain the Vascular Effects of Proton Pump Inhibitors? Circ. Res. 118, 1858–1860.

171. Mason, R.P., Walter, M.F., Day, C.A., and Jacob, R.F. (2007). A biological rationale for the cardiotoxic effects of rofecoxib: comparative analysis with other COX-2 selective agents and NSAids. Subcell. Biochem. 42, 175–190.

172. Chandra, M., and Kent, P.J. (2009). Cyclo-oxygenase-2 Inhibitors and Peripheral Thrombosis—A Case Report Demonstrating a Possible Adverse Effect. EJVES Extra 17, 14–16.

173. Carnieto, A., Jr., Dourado, P.M.M., Luz, P.L., and Chagas, A.C.P. (2009).Selective cyclooxygenase-2 inhibition protects against myocardial damage in experimental acute ischemia. Clinics (São Paulo) 64, 245–252.

174. Keserü, G.M. (2003). Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods. Bioorg. Med. Chem. Lett. 13, 2773–2775.

175. Wang, X., Ryu, D., Houtkooper, R.H., and Auwerx, J. (2015). Antibiotic use and abuse: a threat to mitochondria and chloroplasts with impact on research, health, and environment. BioEssays 37, 1045–1053.

176. Ridley, J.M., Dooley, P.C., Milnes, J.T., Witchel, H.J., and Hancox, J.C. (2004). Lidoflazine is a high affinity blocker of the HERG K(+)channel. J. Mol. Cell. Cardiol. 36, 701–705.

177. Anderson, J.L., Platia, E.V., Hallstrom, A., Henthorn, R.W., Buckingham, T.A., Carlson, M.D., and Carson, P.E. (1994). Interaction of baseline characteristics with the hazard of encainide, flecainide, and moricizine therapy in patients with myocardial infarction. A possible explanation for increased mortality in the Cardiac Arrhythmia SuppressionTrial (CAST). Circulation 90, 2843–2852.

178. Waldo, A.L., Camm, A.J., deRuyter, H., Friedman, P.L., MacNeill, D.J., Pauls, J.F., Pitt, B., Pratt, C.M., Schwartz, P.J., and Veltri, E.P. (1996). Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol. Lancet 348, 7–12.

179. Keber, L., Torp-Pedersen, C., McMurray, J.J.V., Gatzche, O., Livy, S., Crijns, H., Amlie, J., and Carlsen, J.; Dronedarone Study Group (2008). Increased mortality after dronedarone therapy for severe heart failure. N. Engl. J. Med. 358, 2678–2687.

180. Connolly, S.J., Camm, A.J., Halperin, J.L., Joyner, C., Alings, M., Arena, J., Atar, D., Avezum, Á., Blomström, P., Borggreve, M., et al.; PALLAS Investigators (2011). Dronedarone in high-risk permanent atrial fibrillation. N. Engl. J. Med. 365, 2268–2276.

181. Maru, S., Koch, G.G., Stender, M., Clark, D., Gibowski, L., Petri, H., White, A.D., and Simpson, R.J., Jr. (2005). Antidiabetic drugs and heart failure risk in patients with type 2 diabetes in the U.K. primary care setting. Diabetes Care 28, 20–26.

182. Henninger, C., and Fritz, G. (2017). Statins in anthracycline-induced cardiotoxicity: Rac and Rho, and the heartbreakers. Cell Death Dis. 8, e2564.

183. Bromage, D.I., and Yellon, D.M. (2015). The pleiotropic effects of metformin: time for prospective studies. Cardiovasc. Diabetol. 14, 109.

184. Lee, J.W., Morris, J.K., and Wald, N.J. (2016). Grapefruit Juice and Statins. Am. J. Med. 129, 26–29.

185. Wang, Y.-C., Hsieh, T.-C., Chou, C.-L., Wu, J.-L., and Fang, T.-C. (2016). Risks of Adverse Events Following Coprescription of Statins and Calcium Channel Blockers: A Nationwide Population-Based Study. Medicine (Baltimore) 95, e2487.

186. Arunachalam, G., Upadhyay, R., Ding, H., and Triggle, C.R. (2015). MicroRNA Signature and Cardiovascular Dysfunction. J. Cardiovasc. Pharmacol. 65, 419–429.

187. Chistiakov, D.A., Orekhov, A.N., and Bobryshev, Y.V. (2016). Cardiac-specific miRNA in cardiogenesis, heart function, and cardiac pathology in patients with focus on myocardial infarction). J. Mol. Cell. Cardiol. 94, 107–121.

188. Rodriguez, B., Carusi, A., Abi-Gerges, N., Ariga, R., Britton, O., Bub, G., Bueno-Orovio, A., Burton, R.A.B., Carapella, V., Cardone-Noott, L., et al. (2016). Human-based approaches to pharmacology and cardiology: an interdisciplinary and intersectorial workshop. Europace 18, 1287–1298.

189. Mamoshina, P., Bueno-Orovio, A., and Rodriguez, B. (2020). Dual transcriptomic and molecular machine learning predicts all major clinical forms of drug cardiotoxicity. Front. Pharmacol. 11, 639.